

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 9887)

CLARIFICATION ANNOUNCEMENT

Reference is made to the two announcements (the “**Announcements**”) of Nanjing Leads Biolabs Co., Ltd. (the “**Company**”) dated October 16, 2025 in relation to the entry into the Exclusive Global License Agreement. Unless otherwise defined, capitalised terms used in this announcement shall have the meanings as those defined in the Announcements.

The Company wishes to clarify that, compared to the first announcement (the “**First Announcement**”) published at 8:48 pm on October 16, 2025 on the “HKEX news” website, paragraph 4 on page 1 of the second announcement (the “**Revised Announcement**”) published at 10:36 p.m. on October 16, 2025 on the “HKEX news” website, includes the following additional text:

“(including an upfront payment of US\$20 million, US\$5 million in the fourth quarter of 2025 and potential near-term milestone payments up to US\$13 million)”

The Company has included an additional text on the Revised Announcement to enhance transparency by providing investors with more detailed information of potential near-term milestone payments. As a result, the Revised Announcement supersedes the First Announcement.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
*Chairman, Executive Director and
Chief Executive Officer*

Nanjing, the People's Republic of China, October 17, 2025

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Ni Jia as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive directors.